Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (Nasdaq: COO) is a global medical device company with two main business units, CooperVision and CooperSurgical, and its news flow reflects this mix of vision care and women’s health activities. Company press releases regularly provide updates on quarterly and annual financial results, including revenue, earnings per share, margins, and free cash flow, along with commentary from management on operational performance and priorities.
Investors following COO news will see detailed segment information for CooperVision and CooperSurgical, such as revenue by product category and geography, as well as explanations of non‑GAAP metrics, constant currency growth, and organic growth. Releases also describe reorganization and integration efforts, business optimization charges, and product line exits, offering context on how these actions affect reported margins and future cost structure.
CooperCompanies’ news also covers corporate governance and strategic topics. Recent announcements include changes in Board leadership, the appointment of new independent directors, and a formal strategic review of the company’s businesses, corporate structure, and capital allocation priorities. The company has disclosed cooperation agreements with investment partners and expansions of its share repurchase program, including a Board‑approved increase that brought total authorization to $2 billion.
In addition, CooperCompanies issues notices about upcoming earnings releases, conference calls, and participation in healthcare investment conferences, where senior executives present and answer questions. For those interested in the broader eye care landscape, external communications related to CooperVision highlight its role in contact lenses and myopia management. This news page brings together these financial, strategic, and industry‑related updates in one place for users tracking COO.
CooperCompanies (NYSE: COO) has received approval from the Chinese National Medical Products Administration (NMPA) for its MiSight® 1 day contact lenses. This innovative lens targets the growing issue of myopia in children aged 8-12, potentially slowing axial length progression. With an estimated 80% prevalence of myopia among high school students in China, this approval positions Cooper to collaborate with eye-care professionals effectively. The company plans to share more details in its earnings call on September 2, 2021.
CooperCompanies (NYSE: COO) will release its third quarter 2021 financial results on September 2, 2021, at 4:15 PM ET. A conference call to discuss the results will follow at 5:00 PM ET, with the live dial-in available for U.S. listeners at 855-643-4430 and international listeners at 707-294-1332. The call will also be accessible via a webcast on the company's website. A recording of the call will be available from 8:00 PM ET on September 2 to September 9, 2021.
CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, set for payment on August 11, 2021. Stockholders of record must hold shares by July 27, 2021. This decision aligns with the board's approved plan for annual dividends, reflecting the company’s commitment to returning value to shareholders. CooperCompanies operates through CooperVision and CooperSurgical, focusing on innovative medical devices.
CooperVision has announced a partnership with Plastic Bank to introduce the clariti® 1 day lens as the first net plastic neutral contact lens in the U.S. Since January 2021, for every box sold, CooperVision purchases credits from Plastic Bank to offset plastic waste. This move not only enhances eye health with silicone hydrogel technology but also addresses environmental concerns by reducing ocean-bound plastic waste. The lenses are sustainably manufactured in a LEED Silver-certified facility in Costa Rica, powered by renewable energy sources.
CooperCompanies (NYSE: COO) released its inaugural Environmental, Social, and Governance (ESG) Report, showcasing its commitment to ethical practices and social responsibility. Highlights include a partnership with Plastic Bank® for net plastic neutral contact lenses and sourcing 100% renewable electricity for key facilities. The report emphasizes diversity, with women comprising 48% of the workforce and achieving gender parity on the Board. Cooper's goals align with the United Nations Sustainable Development Goals, particularly in health and well-being. The company aims to enhance global health through innovation and responsible practices.
CooperCompanies (NYSE: COO) reported a 37% year-over-year revenue increase to $719.5 million for the fiscal Q2 ended April 30, 2021. CooperVision revenue grew 30% to $522.6 million, and CooperSurgical surged 60% to $196.9 million. GAAP diluted EPS was $2.36, up from $2.13, while non-GAAP diluted EPS reached $3.38, a 123% increase. The operating margin improved to 20%, compared to 5% last year. Fiscal year 2021 revenue guidance has been updated to $2.855-$2.885 billion, reflecting ongoing recovery from COVID-19 impacts.
CooperVision Specialty EyeCare announced the European approval of its Procornea DreamLite® night lenses for slowing myopia progression in children. This product adds to CooperVision's extensive portfolio, which includes MiSight® and SightGlass Vision technologies. A recent study revealed DreamLite lenses reduced axial length growth by 63% in high myopes. The increase in myopia prevalence globally is alarming, projected to affect 5 billion by 2050, leading to serious vision risks. The company's innovations aim to support eye care professionals in addressing this escalating issue.
CooperCompanies has elected Dr. Maria Rivas as an independent director, effective July 1, 2021. Dr. Rivas brings extensive experience in fertility, medical affairs, and product development from her role at Merck KGaA. Al White, CEO, expressed confidence in her contributions as the company seeks growth. The Board now consists of eight directors, with six being independent, highlighting a strengthened governance structure. This follows recent appointments and changes in leadership aimed at enhancing strategic oversight, as part of Cooper's ongoing commitment to improving corporate governance.
CooperCompanies (NYSE: COO) announced the acquisition of obp Medical Corporation for approximately $60 million. obp Medical specializes in single-use vaginal speculums with integrated LED illumination, contributing around $10 million in trailing twelve-month revenue. This acquisition aligns with CooperSurgical's focus on enhancing women's healthcare and is expected to be neutral to non-GAAP earnings per share in fiscal 2021.
CooperCompanies (NYSE: COO) will release its second quarter 2021 financial results on June 3, 2021, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss these results and corporate developments. Participants can join the call by dialing 855-643-4430 (U.S.) or 707-294-1332 (International), using the passcode 'Cooper'. A live webcast will also be available on their Investor Relations website, with a transcript archived for 12 months. The call recording will be accessible from June 3, 8:00 PM ET through June 10, 2021.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
